(Press-News.org) Contact information: Teresa Herbert
teresa_herbert@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute
Novel drug regimen can improve stem cell transplantation outcomes
Bortezomib (Velcade) reduces GVHD, boosts survival
NEW ORLEANS— Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease (GVHD) results in improved outcomes for patients receiving stem-cell transplants from mismatched and unrelated donors, according to researchers from Dana-Farber Cancer Institute.
In a new phase 2 trial, patients treated with bortezomib had lower rates of severe acute GVHD and treatment-related mortality, and experienced better one-year overall survival than has been seen historically with such patients receiving standard preventive therapy, the investigators reported at the American Society of Hematology annual meeting.
"This regimen appears to improve not just GVHD prevention but more importantly, overall and relapse-free survival for myeloablative transplant recipients lacking matched sibling donors," said John Koreth, MBBS, DPhil, of Dana-Farber, the lead author and study PI. The senior author is Edwin P. Alyea, III, MD, also of Dana-Farber.
Stem cell transplantation following myeloablation (high-dose chemotherapy to wipe out the patient's bone marrow and immune system) is a curative therapy in advanced or aggressive hematologic malignancies, Koreth said. However, recipients who lack preferred matched sibling donors have worse outcomes, with higher treatment-related mortality and severe GVHD, and poorer survival.
Bortezomib, a proteasome inhibitor drug, is a mainstay of treatment for multiple myeloma. In addition to killing cancer cells, bortezomib dampens some immune responses, suggesting it may have a role in mitigating GVHD, the result of donor immune cells attacking the transplant recipient's normal tissues.
The prospective, single-arm phase 2 trial of a bortezomib-based regimen enrolled 34 patients with hematologic malignancies who received myeloablative stem cell transplants. In addition to standard GVHD prophylaxis medications – tacrolimus and methotrexate - the patients received three doses of bortezomib (on the first, fourth and seventh day after transplant). The treatment was well-tolerated with no patients missing doses because of toxicity.
Historically, recipients of unrelated and mismatched donor transplants have severe acute GVHD rates of 28 percent and 37 percent, respectively, with one-year treatment-related mortality of 36 percent and 45 percent, respectively, and one-year overall survival of 52 percent and 43 percent, respectively.
In patients treated with bortezomib in the new study, the rate of severe acute GVHD at 180 days after transplant was only 12 percent. By two years, only 8.8 percent of patients had died from treatment-related mortality, and 5.9 percent had died from disease relapse. Overall survival at two years was high at 84 percent.
Koreth said that a randomized trial of bortezomib for GVHD prevention is ongoing at Dana-Farber.
INFORMATION:
Additional authors include Haesook Kim, PhD, and Joseph Antin, MD, both of Dana-Farber.
The research was supported by National Cancer Institute grant P01 CA142106 and by Millennium Pharmaceuticals and Otsuka Pharmaceutical Co.
Novel drug regimen can improve stem cell transplantation outcomes
Bortezomib (Velcade) reduces GVHD, boosts survival
2013-12-08
ELSE PRESS RELEASES FROM THIS DATE:
Flipping a gene switch reactivates fetal hemoglobin, may reverse sickle cell disease
2013-12-08
Flipping a gene switch reactivates fetal hemoglobin, may reverse sickle cell disease
In lab studies, CHOP researchers reprogram gene expression, showing proof-of-concept for potential therapy
Hematology researchers at The Children's Hospital ...
Survey: Knowledge about HPV vaccine effectiveness lacking
2013-12-08
Survey: Knowledge about HPV vaccine effectiveness lacking
ATLANTA — Knowledge about the efficacy of the human papillomavirus (HPV) vaccine in preventing cervical cancer was lacking in the majority of survey respondents for whom the information ...
Certain genetic alterations may explain head and neck cancer survival disparities
2013-12-08
Certain genetic alterations may explain head and neck cancer survival disparities
ATLANTA — Certain genetic alterations to the PAX gene family may be responsible for survival disparities seen between African-American and non-Latino white men ...
Genetic mutations and molecular alterations may explain racial differences in head and neck cancers
2013-12-08
Genetic mutations and molecular alterations may explain racial differences in head and neck cancers
Study helps explain why 'survival gap' persists for African-Americans
A team of scientists at Johns Hopkins and in Texas has identified a handful of genetic mutations ...
Age shouldn't limit access to transplants for MDS, study suggests
2013-12-08
Age shouldn't limit access to transplants for MDS, study suggests
NEW ORLEANS— Patients with myelodysplastic syndromes (MDS) who were as old as 74 fared as well with stem cell transplantation as did patients in the 60-to-65 age range, according ...
Rare cause of anemia in newborns often overlooked, research suggests
2013-12-08
Rare cause of anemia in newborns often overlooked, research suggests
Scientists recommend testing for Pearson syndrome in patients with congenital anemia
Some babies diagnosed with and treated for a bone marrow failure disorder, called Diamond Blackfan ...
T cell immunotherapy: Promising results in children and adults with leukemia
2013-12-07
T cell immunotherapy: Promising results in children and adults with leukemia
Researchers from The Children's Hospital of Philadelphia and University of Pennsylvania harness engineered T cells to eliminate tumors in blood
Nearly 90 percent of ...
High-tech gene-therapy advances offer hope for patients with hard-to-treat blood disorders
2013-12-07
High-tech gene-therapy advances offer hope for patients with hard-to-treat blood disorders
(NEW ORLEANS, December 7, 2013) – A series of advancements in genetically engineered cell therapies demonstrate early efficacy and safety in patients ...
Advances in stem cell transplantation strategies show promise to improve availability, success
2013-12-07
Advances in stem cell transplantation strategies show promise to improve availability, success
(NEW ORLEANS, December 7, 2013) – Hematopoietic stem cell transplantation (HSCT), once considered an effective yet risky alternative to drug ...
International gene therapy trial for 'bubble boy' disease shows promising early results
2013-12-07
International gene therapy trial for 'bubble boy' disease shows promising early results
8 of 9 children treated doing well, according to data presented to American Society of Hematology
(NEW ORLEANS, December 7, 2013) – Hematopoietic stem cell transplantation ...
LAST 30 PRESS RELEASES:
Personalised “cocktails” of antibiotics, probiotics and prebiotics hold great promise in treating a common form of irritable bowel syndrome, pilot study finds
Experts developing immune-enhancing therapies to target tuberculosis
Making transfusion-transmitted malaria in Europe a thing of the past
Experts developing way to harness Nobel Prize winning CRISPR technology to deal with antimicrobial resistance (AMR)
CRISPR is promising to tackle antimicrobial resistance, but remember bacteria can fight back
Ancient Maya blessed their ballcourts
Curran named Fellow of SAE, ASME
Computer scientists unveil novel attacks on cybersecurity
Florida International University graduate student selected for inaugural IDEA2 public policy fellowship
Gene linked to epilepsy, autism decoded in new study
OHSU study finds big jump in addiction treatment at community health clinics
Location, location, location
Getting dynamic information from static snapshots
Food insecurity is significant among inhabitants of the region affected by the Belo Monte dam in Brazil
The Society of Thoracic Surgeons launches new valve surgery risk calculators
Component of keto diet plus immunotherapy may reduce prostate cancer
New circuit boards can be repeatedly recycled
Blood test finds knee osteoarthritis up to eight years before it appears on x-rays
April research news from the Ecological Society of America
Antimicrobial resistance crisis: “Antibiotics are not magic bullets”
Florida dolphin found with highly pathogenic avian flu: Report
Barcodes expand range of high-resolution sensor
DOE Under Secretary for Science and Innovation visits Jefferson Lab
Research expo highlights student and faculty creativity
Imaging technique shows new details of peptide structures
MD Anderson and RUSH unveil RUSH MD Anderson Cancer Center
Tomography-based digital twins of Nd-Fe-b magnets
People with rare longevity mutation may also be protected from cardiovascular disease
Mobile device location data is already used by private companies, so why not for studying human-wildlife interactions, scientists ask
Test reveals mice think like babies
[Press-News.org] Novel drug regimen can improve stem cell transplantation outcomesBortezomib (Velcade) reduces GVHD, boosts survival